Navigation Links
Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
Date:10/25/2012

A new Ebola virus study resulting from a widespread scientific collaboration has shown promising preliminary results, preventing disease in infected nonhuman primates using monoclonal antibodies.

In this week's online edition of the Proceedings of the National Academy of Sciences (PNAS), the research team describes a proof-of-concept for using a "cocktail" of monoclonal antibodies, or mAbs, to prevent lethal disease in rhesus macaques. When administered one hour after infection, all animals survived. Two-thirds of the animals were protected even when the treatment, known as MB-003, was administered 48 hours after infection.

Ebola virus, which causes hemorrhagic fever with human case fatality rates as high as 90 percent, has been responsible for numerous deaths in central Africa over the past several months. In addition to being a global health concern, the virus also is considered a potential biological threat agent. Currently there are no available vaccines or treatments approved for use in humans.

The work is the culmination of more than a decade of effort between government and industry partners. According to lead investigator Gene Olinger, Ph.D., a virologist at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID), this consortium of investigators has taken very distinct technologies and combined them to develop a cutting-edge medical countermeasure against a lethal viral disease.

"It is rare that an antiviral compound prevents Ebola virus infection with limited to no morbidity in treated animals at any point of treatment following infection by this lethal virus," said Olinger. "Until recently, attempts to utilize antibodies to provide protection against Ebola virus have been met with failure. The level of protection against disease that we saw with MB-003 was impressive."

In addition, the production method used in this study offers the potential to make an economical and effective medical countermeasure, according to the authors. Initially developed as a monoclonal antibody cocktail in the mouse model, MB-003 was successfully humanized and then produced in the tobacco plant-based production system.

"We were pleased to see how well the humanized mAbs of MB-003 performed," said Larry Zeitlin, Ph.D., president of Mapp Biopharmaceutical and senior author on the study. "We also were pleasantly surprised by the superiority of the plant-derived mAbs compared to the same mAbs produced in traditional mammalian cell culture."

Further improvement in antibody efficacy was developed at Kentucky BioProcessing (KBP). Using a fully automated production system that operates in accordance with good manufacturing practices (GMP), antibody is produced in a tobacco plant system. This new development process significantly decreases the amount of time required for production, increases the quantity of antibody produced, and slashes the cost of manufacturing, according to Barry Bratcher, chief operating officer of KBP and co-author on the PNAS study.

"Our GMP facility can generate a new antibody lot in two weeks to rapidly address new threats and new outbreaks," said Bratcher.

Olinger said efforts are underway to advance MB-003 to clinical safety testing as his team at USAMRIID continues to determine the true therapeutic capability of the cocktail.


'/>"/>

Contact: Caree Vander Linden
caree.vanderlinden@us.army.mil
US Army Medical Research Institute of Infectious Diseases
Source:Eurekalert

Related biology technology :

1. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
2. Oncobiologics, Inc. Announces a Collaboration Agreement with XOMA Corporation to Utilize XOMAs Fully Human Antibody Libraries for Their Discovery Platform
3. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
4. RayBiotech, Inc. and the University of Oslo Enter into Antibody Array Services Collaboration
5. Sinovac to Present at 55th Annual BioPharma China Convention 2012 - Vaccine & Antibody Focus
6. Acute Lymphocytic Leukemia: Impressive Results With the Monoclonal Antibody Blinatumomab in Patients With Refractory Disease
7. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
8. AnaptysBio Announces Antibody Discovery Partnership With Gilead Sciences
9. Quest Diagnostics STRATIFY JCV™ First FDA Market Authorized Antibody-based Blood Test to Help Stratify PML Risk in Multiple Sclerosis Patients
10. AnaptysBio Announces New Strategic Antibody Discovery
11. Epitomics, Inc. and University of California, Davis, Complete Star Program for High-Throughput Measurement of Antibody-Antigen Interactions
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Feb. 24, 2017  OncoSec Medical Incorporated ("OncoSec") (NASDAQ: ... host a Key Opinion Leader event to highlight new ... and poster presentation at the upcoming 2017 ASCO-SITC Immuno-Oncology ... event will be held in-person and via live webcast ... 9:00 AM PST at the Lotte New York Palace ...
(Date:2/23/2017)... , Feb. 23, 2017  MIODx announced today ... two key immunotherapy technologies from the University of ... a method to monitor a patient for response ... and CTLA-4.  The second license extends the technology ... is likely to have an immune-related adverse event ...
(Date:2/23/2017)... , ... February 23, 2017 ... ... announced today that in a published evaluation of multiple immunoassay-based threat detection ... Department of Energy Laboratory, PathSensors’ CANARY® biosensor threat detection technology was found ...
(Date:2/23/2017)... SAN DIEGO , Feb. 23, 2017 /PRNewswire/ ... protein research tools, announced the acquisition of GenWay ... with a comprehensive service and product offering for ... "This acquisition will facilitate growth and enhance capabilities ... proteins, antibodies, and ELISA assays will nicely complement ...
Breaking Biology Technology:
(Date:1/31/2017)... 31, 2017  Spero Therapeutics, LLC, a biopharmaceutical ... treatment of bacterial infections, today announced it has ... from Pro Bono Bio Ltd (PBB) to bolster ... resistant forms of Gram-negative bacteria.   The assets acquired ... a PBB group company. "The acquisition ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
(Date:1/21/2017)... DUBLIN , Jan 20, 2017 Research ... Recognition Biometrics Market 2017-2021" report to their offering. ... The global voice recognition ... period 2017-2021. The report covers the present scenario ... for 2017-2021. To calculate the market size, the report considers the ...
Breaking Biology News(10 mins):